Stable COPD Treatment: Where are We?

References

• Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256–76. doi:10.1164/ajrccm.163.5.2101039. PMID:11316667.
   PubMedGoogle Scholar
• Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med. August 2012. doi:10.1164/rccm.201204-0596PP.
   Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3). doi:10.1183/13993003.00214-2017.
   Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, et al. Global strategy for the diagnosis, management, and prevention of COPD – 2006 Update. Am J Respir Crit Care Med. 2007;176:532–55. doi:10.1164/rccm.200703-456SO. PMID:17507545.
   PubMed Web of Science ®Google Scholar
• Lacasse Y, Cates CJ, McCarthy B, Welsh EJ. This cochrane review is closed: deciding what constitutes enough research and where next for pulmonary rehabilitation in COPD. Cochrane Database Syst Rev. 2015;(11):ED000107. doi:10.1002/14651858.ED000107. PMID:26593129.
   PubMed Web of Science ®Google Scholar
• Nibber A, Chisholm A, Soler-Cataluña JJ, Alcazar B, Price D, Miravitlles M. Validating the concept of COPD control: A real-world cohort study from the United Kingdom. COPD. 2017;14(5):504–12. doi:10.1080/15412555.2017.1350154. PMID:28813176.
   PubMedGoogle Scholar
• Aguilaniu B, Roche N. The difficulties of measuring and improving physical activity in COPD. NPJ Prim Care Respir Med. 2014;24:14014. doi:10.1038/npjpcrm.2014.14. PMID:24841568.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181. doi:10.1186/1741-7015-11-181. PMID:23945277.
   PubMed Web of Science ®Google Scholar
• Faner R, Sibila O, Agustí A, Bernasconi E, Chalmers JD, Huffnagle GB, Manichanh C, Molyneaux PL, Paredes R, Pérez Brocal V, et al. The microbiome in respiratory medicine: current challenges and future perspectives. Eur Respir J. 2017;49(4):1602086. doi:10.1183/13993003.02086-2016. PMID:28404649.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015;385(9979):1789–98. doi:10.1016/S0140-6736(15)60693-6. PMID:25943943.
   PubMed Web of Science ®Google Scholar
• Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22(1):92–100. doi:10.4104/pcrj.2012.00092. PMID:23135217.
   PubMedGoogle Scholar
• Bulpa P, Bihin B, Dimopoulos G, Taccone FS, Van den Abeele A-M, Misset B, Meersseman W, Spapen H, Cardoso T, Charles P-E, et al. Which algorithm diagnoses invasive pulmonary aspergillosis best in ICU patients with COPD? Eur Respir J. 2017;50(3):1700532. doi:10.1183/13993003.00532-2017. PMID:28954783.
   PubMed Web of Science ®Google Scholar
• Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68(3):256–62. doi:10.1136/thoraxjnl-2012-201772. PMID:22781123.
   PubMed Web of Science ®Google Scholar
• Dong Y-H, Chang C-H, Lin Wu F-L, Shen L-J, Calverley PMA, Löfdahl C-G, Lai M-S, Mahler DA. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145(6):1286–97. doi:10.1378/chest.13-2137. PMID:24504044.
   PubMed Web of Science ®Google Scholar
• Wang M-T, Liou J-T, Lin CW, Tsai C-L, Wang Y-H, Hsu Y-J, Lai J-H. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178(2):229–38. doi:10.1001/jamainternmed.2017.7720. PMID:29297057.
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, Scichilone N, Sestini P, Aliani M, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–8. doi:10.1016/j.rmed.2011.01.005. PMID:21367593.
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, Droz-Perroteau C, Lassalle R, Moore N, Girodet P-O. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2):1601794. doi:10.1183/13993003.01794-2016. PMID:28182569.
   PubMed Web of Science ®Google Scholar
• Han MK, Quibrera PM, Carretta EE, Barr RG, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–26. doi:10.1016/S2213-2600(17)30207-2. PMID:28668356.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–38. doi:10.1056/NEJMoa0909883. PMID:20843247.
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–5. doi:10.1164/rccm.201310-1863PP. PMID:24383418.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger J-B, Signorovitch JE. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:367–81. doi:10.2147/COPD.S119908. PMID:28176892.
   PubMed Web of Science ®Google Scholar
• Zysman M, Chabot F, Housset B, Morelot Panzini C, Devillier P, Roche N, Société de Pneumologie de Langue Française. Pharmacological treatment optimisation for stable COPD: an endless story? Proposals from the Société de Pneumologie de Langue Française. Eur Respir J. 2017;50(4). doi:10.1183/13993003.01250-2017. PMID:29025880.
   PubMed Web of Science ®Google Scholar
• Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I, Ovcharenko S, Shmelev E, Miravitlles M. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int J Chron Obstruct Pulmon Dis. 2018;13:183–7. doi:10.2147/COPD.S153770. PMID:29386887.
   PubMed Web of Science ®Google Scholar
• Kankaanranta H, Harju T, Kilpeläinen M, Mazur W, Lehto JT, Katajisto M, Peisa T, Meinander T, Lehtimäki L. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol. 2015;116(4):291–307. doi:10.1111/bcpt.12366. PMID:25515181.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Anzueto A. A new two-step algorithm for the treatment of COPD. Eur Respir J. 2017;49(2):1602200. doi:10.1183/13993003.02200-2016. PMID:28179443.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, Kankaanranta H, Sandström T, Śliwiński P, Zatloukal J, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016:47(2):625–37. doi:10.1183/13993003.01170-2015. PMID:26797035.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MPMH, Beeh KM, Rabe KF, Fabbri LM. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–103. doi:10.1056/NEJMoa1008378. PMID:21428765.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89. doi:10.1056/NEJMoa063070. PMID:17314337.
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81. doi:10.1183/09031936.03.00031402. PMID:12570112.
   PubMed Web of Science ®Google Scholar
• Singh D, Kampschulte J, Wedzicha JA, Jones PW, Cohuet G, Corradi M, Higenbottam T, Petruzzelli S, Vestbo J. A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. Eur Respir J. 2013;41(1):12–7. doi:10.1183/09031936.00207611. PMID:22653766.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–34. doi:10.1056/NEJMoa1516385. PMID:27181606.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Chapman KR, Singh D, D'Urzo AD, Molins E, Leselbaum A, Gil EG. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92. doi:10.1186/s12931-015-0250-2. PMID:26233481.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG. Translational study searching for synergy between glycopyrronium and indacaterol. COPD. 2015;12(2):175–81. doi:10.3109/15412555.2014.922172. PMID:25222881.
   PubMedGoogle Scholar
• Beeh K-M, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, Banerji D. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108(4):584–92. doi:10.1016/j.rmed.2014.01.006. PMID:24534204.
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–73. doi:10.1016/S0140-6736(16)31354-X. PMID:27598678.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017;389(10082):1919–29. doi:10.1016/S0140-6736(17)30188-5. PMID:28385353.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu C-Q, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–46. doi:10.1164/rccm.201703-0449OC. PMID:28375647.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–94. doi:10.1056/NEJMoa1407154. PMID:25196117.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindale S, Collier S, Crawford J, Frith L, Harvey C, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253–60. doi:10.1056/NEJMoa1608033. PMID:27593504.
   PubMed Web of Science ®Google Scholar
• Bosnic-Anticevich S, Chrystyn H, Costello RW, Dolovich MB, Fletcher MJ, Lavorini F, Rodríguez-Roisin R, Ryan D, Wan Yau Ming S, Price DB. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis. 2017;12:59–71. doi:10.2147/COPD.S117196. PMID:28053517.
   PubMed Web of Science ®Google Scholar
• Roche N, Reddel HK, Agusti A, Bateman ED, Krishnan JA, Martin RJ, Papi A, Postma D, Thomas M, Brusselle G, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med. 2013;1(10):e29–30. doi:10.1016/S2213-2600(13)70199-1. PMID:24461762.
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Kerkhof M, Soriano JB, Mikkelsen H, Price DB. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir Res. 2016;17(1):120. doi:10.1186/s12931-016-0433-5. PMID:27663386.
   PubMed Web of Science ®Google Scholar
• Herland K, Akselsen J-P, Skjønsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med. 2005;99(1):11–19. doi:10.1016/j.rmed.2004.03.026. PMID:15672843.
   PubMed Web of Science ®Google Scholar
• Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604. doi:10.1164/rccm.200912-1843CC. PMID:20522794.
   PubMed Web of Science ®Google Scholar
• Burgel P-R, Paillasseur J-L, Roche N. Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities. BioMed Res Int. 2014;2014:420134. doi:10.1155/2014/420134. PMID:24683548.
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Gómez FP, Benet M, Farrero E, Basagaña X, Gayete À, Paré C, Freixa X, Ferrer J, Ferrer A, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430–7. doi:10.1136/thx.2010.154484. PMID:21177668.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Calverley PMA, Goehring U-M, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015;385(9971):857–66. doi:10.1016/S0140-6736(14)62410-7. PMID:25684586.
   PubMed Web of Science ®Google Scholar
• Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, Criner GJ, Casaburi R, Connett J, Lazarus SC, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189(12):1503–8. doi:10.1164/rccm.201402-0207OC. PMID:24779680.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Respir Med. 2017;5:747–759. doi:10.1016/S2213-2600(17)30217-5.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot J-B, Sagara H, Albers FC, Bradford ES, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–29. doi:10.1056/NEJMoa1708208. PMID:28893134.
   PubMed Web of Science ®Google Scholar
• Roche N, Zysman M, Burgel P-R. Blood eosinophil counts as a guide for COPD treatment strategies. Lancet Respir Med. January 2018. doi:10.1016/S2213-2600(18)30005-5.
   PubMed Web of Science ®Google Scholar
• Agustí A, Celli B, Faner R. What does endotyping mean for treatment in chronic obstructive pulmonary disease? Lancet 2017;390:980–7. doi:10.1016/S0140-6736(17)32136-0. PMID:28872030.
   PubMed Web of Science ®Google Scholar
• Agusti A, Gea J, Faner R. Biomarkers, the control panel and personalized COPD medicine. Respirol Carlton Vic. 2016;21(1):24–33. doi:10.1111/resp.12585.
   PubMed Web of Science ®Google Scholar
• Oh DK, Kim Y-S, Oh Y-M. Lung regeneration therapy for chronic obstructive pulmonary disease. Tuberc Respir Dis. 2017;80(1):1–10. doi:10.4046/trd.2017.80.1.1.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respir Med. 2014;108(5):729–36. doi:10.1016/j.rmed.2014.03.002. PMID:24675239.
   PubMed Web of Science ®Google Scholar
• Burgel P-R, Deslée G, Jebrak G, Brinchault G, Caillaud D, Chanez P, Court-Fortune I, Escamilla R, Nesme-Meyer P, Paillasseur J-L, et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Eur Respir J. 2014;43(4):1201–3. doi:10.1183/09031936.00162313. PMID:24176996.
   PubMed Web of Science ®Google Scholar
• Boulet L, Becker A, Bowie D, McIvor A, Hernandez P, Rouleau M, Bourbeau J, Graham I, Legare F, Ward T, et al. Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD. Can Respir J. 2006;13(Suppl A):5–47. doi:10.1155/2006/810978. PMID:16552449.
   PubMedGoogle Scholar